Difference between revisions of "Tafasitamab (Monjuvi)"

Revision as of 13:51, 12 June 2017

Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity

Woyach JA, Awan F, Flinn IW, Berdeja JG, Wiley E, Mansoor S, Huang Y, Lozanski G, Foster PA, Byrd JC. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60. Epub 2014 Oct 9. PubMed

Revision as of 02:44, 2 December 2016 (view source) Dryang (talk \| contribs) m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") ← Older edit	Revision as of 13:51, 12 June 2017 (view source) Jwarner (talk \| contribs) m (Jwarner moved page XmAb5574 (MOR00208) to MOR208) Newer edit →
(No difference)